drugset / Trial / NCT00353457
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Phase 2
Terminated
6 enrolled
Abramson Cancer Center at Penn Medicine
Bristol-Myers Squibb · collabRoche Pharma AG · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study of induction chemotherapy (capecitabine, oxaliplatin and cetuximab (erbitux)) followed by capecitabine, oxaliplatin, cetuximab and radiotherapy followed by surgery followed by adjuvant capecitabine, oxaliplatin and cetuximab for locally advanced resectable rectal cancer.
Timeline
- Start
- 2006-02
- Primary completion
- 2011-06
- Completion
- 2011-06
Outcome
Outcome not reported
Stopped: “new studies were finding that Erbitux was not beneficial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |